Avalo Therapeutics Inc.
AVTX | NASDAQ
$16.62
+$0.45 (+2.78%)
Sep 22, 2026, 10:46 AM ET · Market open
90-Day Net Volume
-$2.04M
90-Day Activity
0 Buys / 11 Sales
All-Time Net Volume
$51.69M
Total Filings
981
Insider Trading Activity
| Name | Transaction Date | Transaction Type | Shares | Price | Value |
|---|---|---|---|---|---|
Sullivan Christopher Ryan Chief Financial Officer | Sep 16, 2026 | S-Sale Common Stock | 12,394 | 16.33 | $202,437 |
Sullivan Christopher Ryan Chief Financial Officer | Sep 10, 2026 | S-Sale Common Stock | 10,185 | 17.62 | $179,457 |
Doyle Mittie Chief Medical Officer | Aug 28, 2026 | S-Sale Common Stock | 679 | 20 | $13,580 |
Pro Membership
Stop Guessing, Start Knowing.
Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.
Unlimited access
Unlimited access to all data and tools, giving you the edge over everyone else in the market.
Proprietary Stock Rating Score
Evaluate stocks with our proprietary rating score based on fundamentals, economic moat, and sentiment.
Top Wall Street Analyst Ratings
Follow ratings from the best analysts on Wall Street to stay ahead of market moves.
Up to 30 years financial history
We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.
Add to Watchlist
Select watchlists to add or remove AVTX